iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 11.7% in January

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 213,800 shares, a decrease of 11.7% from the January 15th total of 242,000 shares. Based on an average trading volume of 174,300 shares, the short-interest ratio is currently 1.2 days. Currently, 2.3% of the company’s shares are short sold.

iBio Trading Up 7.3 %

Shares of NYSEAMERICAN IBIO traded up $0.25 during midday trading on Tuesday, hitting $3.68. The company’s stock had a trading volume of 313,736 shares, compared to its average volume of 283,382. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91. iBio has a 1 year low of $1.05 and a 1 year high of $4.98.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.